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Abstract
Background: Functional dyspepsia (FD) is characterized by a high prevalence rate and no standard conventional
treatments. Alternative therapies, such as herbal formulas, are widely used to treat FD. However, there are
inadequate evidences regarding the safety and efficacy of these formulas. Moreover, the mechanisms by which
herbal formulas act in the gastrointestinal tract are controversial. In traditional Korean medicine, Banha-sasim-tang
has long been one of the most frequently prescribed herbal formulas for treating dyspepsia. The current study is
designed to evaluate the efficacy and safety of Banha-sasim-tang for FD patients and to examine whether there
will be a significant correlation between cutaneous electrogastrography recordings and dyspeptic symptoms in FD
patients, and between changes in gastric myoelectrical activity and improvement in dyspeptic symptoms during
Banha-sasim-tang administration.
Methods: This randomized, double-blind, placebo-controlled trial will be performed at two centers and will include
a Banha-sasim-tang group and placebo group. Each group will consist of 50 FD patients. Six weeks of
administration of Banha-sasim-tang or placebo will be conducted. During the subsequent 2 months, follow-up
observations of primary and secondary outcomes will be performed. The primary outcomes are differences as
measured on the gastrointestinal symptom scale, and the secondary outcomes are differences as measured on the
visual analogue scale for dyspepsia and on the questionnaire for FD-related quality of life. All outcomes will be
measured at baseline, at 2, 4, and 6 weeks of treatment, and at the 1 and 2 month follow-up. Cutaneous
electrogastrography will be performed and assessed at baseline and at 6 weeks.
Discussion: This trial will provide evidence of the safety and efficacy of Banha-sasim-tang for the treatment for FD.
Furthermore, based on the assessment of the relationship between cutaneous electrogastrography recordings and
dyspeptic symptoms in this trial, the possibility of clinical applications of cutaneous electrogastrography in the
treatment of FD will be elucidated.
Trial Registration: Current Controlled Trials (ISRCTN 51910678); Clinical Trials.gov Identifier: NCT00987805
Background
Functional dyspepsia (FD) is characterized by chronic or
relapsing dyspeptic symptoms in the absence of struc-
tural lesions that can be identified with clinically avail-
able tests [1,2]. In developed countries, 15-20% of the
general population experiences dyspeptic symptoms at
some point over the course of any given year [3]. An
epidemiologic survey conducted in South Korea
reported that 25% of the population suffers from FD [4].
Although the pathogenic causes of FD remain unclear,
delayed gastric emptying has been found in up to 50%
of FD patients [5]. Delayed gastric emptying may be
attributed to gastric hypomotility and to uncoordinated
antral duodenal contractions [6]. Normal gastric slow
waves originating in the gastric pacemaker lead to nor-
mal frequency and peristaltic gastric contractions [5].
Abnormal gastric myoelectrical dysrhythmias has been
observed in FD patients who have shown delayed gastric
emptying [5]. Cutaneous electrogastrography (EGG) is a
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myoelectrical activity (GMA). Many researchers have
used cutaneous EGG, which suggests that this technique
may be useful in the evaluation of gastric motor func-
tion in FD patients [7]. However, the relationship
between dyspeptic symptoms and cutaneous EGG
recordings remains a controversial topic in FD.
Current treatments for FD target putative underlying
mechanisms, including visceral hypersensitivity,
impaired gastric emptying, and acid hypersensitivity [8].
The symptoms of FD are diverse, thus mechanism-
focused therapies, such as acid secretion inhibitors, pro-
kinetics, and H. pylori eradication, have been used with
limited effects [8-10]. Therefore, many patients use
alternative therapies, including herbal formulas, acu-
puncture treatments, and natural products, to treat FD
[2,11-16].
Banha-sasim-tang (BST; Hange-shashin-to in Kampo
Medicine; Banxia-xiexin-tang in Traditional Chinese
Medicine) is one of the herbal formulas described in
“Treatise on Cold Damage and Miscellaneous Diseases
(Shan-han-za-bing-lin)” [17], the Chinese authoritative
monographs. This formula is composed of seven herbs.
In traditional Korean medicine, this formula has been
applied for treating the symptom “gastric stuffiness”
[17], which is similar to dyspepsia. Recently, several stu-
dies have elucidated the gastric function and related
mechanisms of BST [18-20].
Moreover, BST can be obtained as an over-the-coun-
ter herbal formula in Korea or prescribed for dyspeptic
symptoms by the Traditional Korean Medicine doctors.
For that reason, reliable clinical evidence regarding BST
as treatment for FD is needed. However, there are no
relevant randomized controlled clinical trials regarding
FD as far as we know.
The current study is designed to investigate the
effect of BST on FD and related quality of life. We will
also examine the relationship between the frequency or
power variables in cutaneous EGG and dyspeptic
symptoms of FD patients in this trial and determine
whether the changes in GMA recorded by cutaneous
EGG before and after the oral administration of
BST can reflect the clinical efficacy of BST in the
treatment of FD.
Methods
Objectives
The aims of this study are to:
(1) To determine whether BST can improve dyspeptic
symptoms in patients with FD.
(2) To examine the relationship between dyspeptic
symptoms and cutaneous EGG recordings and a possi-
ble biological evidence of BST’s efficacy via cutaneous
EGG recordings.
Hypothesis
(1) Six weeks of oral administration of BST improves
dyspeptic symptoms and quality of life in patients with
FD.
(2) In patients with FD or FD subtypes according to
the Rome III criteria, there will be a significant correla-
tion between the degree of dyspeptic symptoms and
cutaneous EGG recordings and 6 weeks of oral adminis-
tration of BST can improve the abnormal frequency and
power parameters on cutaneous EGG.
Design
This study will be carried out as a randomized, placebo-
controlled, double-blind, two-center trial at the Oriental
Hospital at Kyung Hee University Medical Center and
at the Oriental Hospital at the East-West Neo Medical
Centre of Kyung Hee University in Seoul, Korea.
This clinical trial will consist of a 6-week oral admin-
istration of BST and a 2-month follow-up period. Before
screening, all participants will go through a 7-day wash-
out phase. During 6 weeks’ administration of experi-
mental drugs, patients will be prohibited from taking
any kind of dyspepsia-relieving drugs. After randomiza-
tion, 3 g TID of BST or placebos will be provided for 6
weeks. Outcomes will be measured at baseline, at 2
weeks, at 4 weeks and at 6 weeks after randomization.
Outcomes will also be measured at 1 month and 2
months after completion of BST administration. During
2-month follow-up period, conventional treatments for
dyspepsia will be permitted if the dyspeptic symptoms
are exacerbated or recur. Any treatment received by the
patient during the follow-up period will be reported by
them or documented in their diary (Figure 1).
This study will be performed in accordance with the
standards of the International Committee on Harmoniza-
tion on Good Clinical Practice and the revised version of
the Declaration of Helsinki. The protocol of the trial has
been approved by two ethics committees: the institu-
tional review boards of both the Oriental Hospital at
Kyung Hee University Medical Center and the Oriental
Hospital at East West Neo Medical Center of Kyung Hee
University. The permission numbers are KOMC IRB
2009-05 for the Oriental Hospital at Kyung Hee Univer-
sity Medical Centre and KHNMC-OH-IRB 2009-001 for
the Oriental Hospital at East-West Neo Medical Centre
of Kyung Hee University. Written informed consent will
be obtained from all participants prior to enrollment, and
patients will be given enough time to decide if they wish
to participate before signing the consent form.
Participants
Inclusion criteria
Patients 19-75 years old who complain of dyspepsia for
the previous 3 months, and who have an onset of
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the Rome III criteria for FD [21]. Patients with one or
more of the following symptoms: postprandial fullness,
early satiety, epigastric pain or burning, will be also con-
sidered as meeting the study definition of FD. Then, all
the participants will undergo endogastroduodenoscopy
(EGD) before enrollment and be examined by gastroen-
terologists to determine whether the EGD observations
are related to the present dyspeptic symptoms. On the
other hand, the Helicobacter pylori status of the patients
and history of H. pylori eradication therapy will be
assessed before enrollment by non-invasive tests (urea
breath test) or the rapid urease test.
Patients who are diagnosed with FD can be categor-
ized as having either 1) meal-induced dyspeptic symp-
toms (postprandial distress syndrome; PDS) or 2)
epigastric pain syndrome (EPS) and, in this trial, all FD
patients will be classified into one of the abovemen-
tioned subtypes (PDS and EPS) [21]. The dyspepsia
severity of patients who meet the Rome III criteria will
be assessed by a validated Gastrointestinal Symptom
(GIS) scale, which measures the severity of 10 symptoms
[22]. The presence of “moderate” as the degree of sever-
ity for at least three GIS scale symptoms will be a basic
criterion for trial inclusion [2].
Exclusion criteria
Patients who report the following conditions will be
excluded:
History of peptic ulcer, gastroesophageal reflux disease
(GERD), gastrointestinal surgery or mental disorders,
marked current symptoms of irritable bowel disease, the
presence of the alarm symptoms such as severe weight
loss, black or tar stool, dysphagia, the presence of
uncontrolled severe organ diseases including cancer,
ingestion of aspirin or nonsteroidal anti-inflammatory
drugs (NSAIDs), and women who are pregnant or
lactating.
At the screening phase, patients who are using any
antibiotic, proton-pump inhibitor, bismuth salt, proki-
netic agents such as itopride, herbal formulas, or who
are participating in any other clinical trial, will be
excluded from this study.
Recruitment
Recruitment will be done through hospitals and with
newspaper advertisements. Patients who have severe
dyspeptic symptoms are likely to receive conservative
therapies. Thus, interested patients with severe symp-
toms of functional dyspepsia may be recruited through
hospitals. However, patients with mild to moderate
symptoms of functional dyspepsia seldom receive regu-
lar hospital treatment. Recruitment advertisements in
newspapers can attract those patients with less severe
symptoms.
Randomization
Randomization will be controlled by an independent
clinical research coordinator( C R C ) .F i r s t ,t h er a n d o m i -
zation form with the basic information of the participant
who has passed the screening phase will be transmitted
in facsimile to the independent statistician. The rando-
mization number in the randomization form will be left
blank before arrival to the statistician. The statistician
will then decide the randomization number based on
the allocation sequence which has been generated by a
random number creation program in advance and the
statistician will return the randomization form filled in
with the established number (specific ID number) to the
CRC. The ratio of randomization allocation to the sites
will be 1:1. The CRC will inform the investigators of the
specific ID number. This procedure will be guaranteed
by the authorized contract research organization (CRO).
Blinding
In this trial, investigators will not be in contact with the
CRC, the clinical pharmacist, or the statistician. The
Figure 1 Flow chart of the trial.
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researchers will not have any influence on enrollment or
randomization. The statistician will receive the randomi-
zation form in facsimile, fill in the blank and return it in
order, thus any contact with other researchers cannot
be made. The blinding procedure will also be verified by
the authorized CRO.
Experimental drugs
Banha-sasim-tang (BST)
BST has long been used in traditional Korean medicine
to treat gastrointestinal diseases. According to recent
experimental researches, BST has been known to reduce
inflammation in inflammatory bowel diseases and diar-
rhea, to regulate gastrointestinal functional in FD, and
to protect against the side effects of chemotherapy in
gastrointestinal cancers [18-20,23,24].
Although many experimental studies suggest that BST
can be used to treat FD, there are no randomized stu-
dies of BST as a treatment for FD as far as we know.
BST used in this trial is a brown, bitter herbal extract
granule (Bansasin granule®, Hanpoong Pharm & Food
Co., Ltd., Jeonju, Korea) produced according to Korean
Good Manufacturing Practice. Bansasin granule® is per-
mitted and regulated by the Korean Food & Drug
Administration. Each 3 g Bansasin granule® (water-
extracted BST mixed with starch and lactose) is com-
posed of seven herbs: Pinelliae Tuber (the rhizome of
Pinellia ternata (Thunb.) Breit., family Araceae) 1.67 g,
Scutellariae Radix (the root of Scutellaria baicalensis
Georgi, family Labiatae) 1.00 g, Ginseng Radix (the root
of Panax ginseng C.A. Meyer, family Araliaceae) 1.00 g,
Glycyrrhizae Radix (the root of Glycyrrhiza uralensis
Fisch., family Leguminosae) 1.00 g, Zizyphi Fructus (the
fruit of Zizyphus jujuba Mill. var. inermis Rehder, family
Rhamnaceae) 1.00 g, Zingiberis Rhizoma (the rhizome of
Zingiberis officinale Roscoe, family Zingiberaceae) 0.83
g, and Coptidis Rhizoma (the rhizome of Coptis chinen-
sis Franch., family Ranunculceae) 0.33 g. As standard
chemical components in each 3 g Bansasin granule®,
11.6 mg of berberin, 25.0 mg of glycyrrhzin acid and
100.0 mg of baicalin are included. Voucher specimens
will be retained at the research laboratory of Hanpoong
Pharm & Food Company. Regular dosage is 3 g TID for
adults while dyspeptic symptoms, nausea, vomiting, diar-
rhea, abdominal pain, and anorexia continue.
Placebo
At present, there is no standard treatment in FD. Thus,
the placebo for this trial requires no active components.
Although Bansasin granule® is not a chemical drug and
relevant drug packagings may be needed for succeeding
blinding, drug packaging, such as starch capsules, will
not be used for reproducing the real situation of
Bansasin granule® administration in this trial. Therefore,
mimicking the original color and taste of the Bansasin
granule® without adding any active components was
quite a difficult procedure. The company that makes the
Bansasin granule® was experienced in making placebos
of herbal extracts and they succeeded in making a Ban-
sasin granule® placebo through the development of
several test samples. The placebo is a starch and lactose
mixture which has a color and taste similar to the Ban-
sasin granule®. Retention samples of placebo used in the
current study will be kept at the Hanpoong Pharm &
Food Company. At the end of the study, the question to
participants whether the drugs that they have taken is
real or not will be answered by themselves for evalua-
tion of success in blinding.
Outcome measures
Primary outcome
The primary outcome is the proof of BST’ss u p e r i o r i t y
compared with placebo in treating FD. For this purpose,
t h eG I Ss c a l ei sc h o s e na st h ep r i m a r yv a r i a b l e[ 1 ] .T h e
primary efficacy parameter is the change in the sum
totals of the GIS scales. The GIS scale is composed of
the following 10 dyspeptic symptoms: epigastric pain/
upper abdominal pain, abdominal cramps, fullness, early
satiety, loss of appetite, malaise, nausea, vomiting, retro-
sternal discomfort, and acidic regurgitation/heartburn.
Symptom severity per each item will be assessed by a 5-
point Likert scale: none - 0, slight - 1, moderate - 2,
severe - 3, and very severe - 4. The GIS scale is very
easy for participants to understand and to complete.
The GIS scale will be assessed at baseline, 2 weeks,
4 weeks and 6 weeks during oral administration of BST,
and at 1 month and 2 months after completion of BST
administration.
Secondary outcomes
A visual analogue scale (VAS) will be used to determine
the patient’s global judgment of intensity of discomfort
due to dyspepsia (ranging from 0 mm as no discomfort
to 100 mm as the most intense discomfort). The VAS
measurements will be performed with the same
frequency as the GIS scale measurements.
The validated Functional Dyspepsia related Quality of
Life (FD-QoL) questionnaire assesses FD’s influence on
quality of life and consists of four categories: diet (5
items), daily activity (4 items), emotion (6 items), and
social functioning (6 items) [25]. FD-QoL will also be
performed with the same frequency as the GIS scale
measurements.
Measurement of GMA
Gastric hypomotility and uncoordinated antral duodenal
contractions in FD patients are closely associated with
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arise from dysregulation of gastric slow waves, which
normally occur at a frequency of 3 cycles per minute
(cpm) [26].
Electrogastrogram records GMA acquired from cuta-
neous abdominal electrodes [27]. Although some
researchers have suggested that some cutaneously
acquired dysrhythmias may be artifactual in nature [28],
other experiments have suggested a positive correlation
between the frequencies found with cutaneous EGG
recordings and myoelectrical signals acquired from gas-
tric serosal leads [29,30].
In this study, the GMAs of the participants will be
measured using surface multichannel EGG (Polygraf ID®,
Medtronic A/S, Denmark) at baseline and at 6 weeks.
This method of EGG measurement will be conducted as
described previously [26]. First, the epigastric skin to be
attached to the electrodes will be shaved and abraded
with a sandy skin preparation jelly to reduce impedence.
Four active surface electrodes will be positioned at the
sites: the corpus of stomach as channel 1, proximal
antrum as channel 2, distal antrum as channel 3, and
pylorus region as channel 4. A ground electrode and a
reference electrode will also be placed. EGG measure-
ments will be performed in a quiet room and patients
will fast over night for ≥ 8 hours. Participants will be
asked not to talk and to remain as still as possible during
the EGG assessment to avoid motion artifacts. Patients
will undergo a 20 minute fasting (preprandial) EGG mea-
surement in the supine position, then they will eat two
scrambled medium eggs and two pieces of toasted bread
with 500 ml of water as the standard solid test meal (500
Kcal). Then, postprandial EGG measurement will be con-
ducted for 40 minutes. The percentage of slow wave cou-
pling, the EGG dominant frequency and power, the
percentage of normal gastric slow waves, the percentage
of gastric dysrhythmia, and the postprandial to prepran-
dial power ratio will be assessed.
Safety
Before randomization and after completion of BST
administration, we will perform the following tests on
all participants: complete blood cell count, AST/ALT,
gGT, BUN, creatinine, erythrocyte sedimentation rate as
well as electrocardiogram. The above tests will serve to
exclude participants who have serious illnesses and
abnormal heart, liver, kidney, or other organ function-
ing. Throughout the study, we will also assess whether 6
weeks of BST administration in FD patients is safe by
above tests or CRF documentations.
The guide for taking BST which are verified by the
Korean Food & Drug Administration lists several
adverse events: pseudoaldosteronism, myopathy, skin
disorders, liver malfunction, pneumonia, or dry mouth.
During the trial, all adverse events will be observed in
detail and documented in case report forms (CRFs).
Quality control
Before starting the trial, investigators who assess the
EGG will receive thorough training in taking EGG
measurements.
To maintain the accuracy and quality of the clinical
trial, audit and monitoring will be conducted by the
Marinet Corporation, a CRO located in Seoul, Korea.
The sites’ CRF completion and compliance with stan-
dard operation procedures will be audited. Clinical
research associates will, at regular periods, monitor the
clinical trial procedures su c ha sc o m p l i a n c ew i t hB S T
administration and voluntary withdrawal of participants.
In particular, reasons for withdrawal will be fully docu-
mented in CRFs.
Statistical analysis
The primary hypothesis is that oral administration of
BST is more effective than placebo for treating FD. We
hope to prove this hypothesis by means of a 2-sided test
yielding a 5% significance level. Because there is no rele-
vant previous study using BST for calculating sample
size, we referred to a similar herbal trial for FD treat-
ment which used the GIS scale [1]. The formula for esti-
mating the sample size is as follows:
nn Z Z tc ct == + + − {( ) ( ) / }/( ) / ab sl l m m 2
22 2 1
The previous trial demonstrated 3.5 points of
improvement (μc - μt = Δ) in the GIS scale over treat-
ment with placebo during 4 weeks of herbal treatments
[1]. The same study indicated a mean standard deviation
(SD = s) of 5.37. In our study, the ratio (l)o fe x p e r i -
mental group to placebo group will be 1:1. With a
power of 80% (1 - b) and significance level of 5% (a),
assuming Δ =3 . 5a n ds =5 . 3 7 ,as a m p l es i z eo fnt =
nc = 37 patients per treatment group will be required.
(nt, number of BST group; nc, number of placebo
group). Considering an assumed dropout rate of 25%, a
total of 100 patients will be needed.
The analysis strategy in this study is as follows:
As a first step, the baseline characteristics of both
g r o u p s ,s e x ,a g e ,d u r a t i o no f dyspeptic periods, and
smoking, will be compared. As a second step, we will
compare the efficacy of BST and placebo, as the change
in GIS totals from the beginning (0 day) to the end (6
weeks) of the study period. As a third step, we will ana-
lyze the secondary variables (VAS and FD-QoL) in the
same manner as we did the GIS scale. Finally, various
parameters in the EGG measurement, such as frequency
and power-related variables will be compared before
and after treatment in both groups. Correlations
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meter findings will also be analyzed.
A l la n a l y s e si nt h i ss t u d yw i l lb eb a s e do nt h ei n t e n -
tion-to-treat principle. If data distribution is skewed
owing to insufficient sample size, relevant transforma-
tion by a statistician prior to analysis will be made. The
baseline characteristics will be compared by either c
2-
test or the Student t-test. Primary and secondary
outcomes will be presented as means and SDs, and ana-
lyzed by independent t-tests, Mann-Whitney tests, or
Wilcoxon singed-rank tests. Correlations between the
GIS scale and EGG parameters will be analyzed by Pear-
son’s correlation coefficients or by Spearman’sR h o .
Adverse events will be calculated and compared using
c
2-test or Fisher’s exact test.
Statistical analyses will be conducted in a blind man-
ner by an independent statistician and performed using
SPSS 16.0 (SPSS inc., Chicago, Illinois, USA).
Discussion
The current clinical study is a randomized, double-blind,
placebo-controlled trial investigating the safety and effi-
cacy of frequently used herbal formulas as part of the
national project for studying the traditional herbal medi-
cines of South Korea. This clinical trial belongs to the
2009 Traditional Korean Medicine R&D projects funded
by the Ministry for Health & Welfare & Family Affairs,
Republic of Korea. BST is one of the most frequently
prescribed herbal formulas in Korea, BST is thought to
be safe, and experimental evidences support BST’s effec-
tiveness for dyspepsia [18-20]. However, there have not
been any randomized controlled trials showing the effec-
tiveness of BST for the treatment of FD. Through the
current study, we expect to gain objective clinical evi-
dences of the efficacy and safety of BST for the treat-
ment of FD.
The causes of functional dyspepsia are diverse and
overlapping. Of the putative causes of FD, delayed gas-
tric emptying/gastric dysmotility is one of the most
important causes of FD in Korea and has been reported
to closely correlate to GMA recorded by cutaneous
EGG [5]. Because many researchers have suggested that
cutaneous EGG could be a relatively easy technique that
can be used to assess GMA in clinical settings and EGG
recordings showed a significant correlation with dyspep-
tic symptoms in FD patients and changes in cutaneous
EGG parameters in FD patients could reflect changes in
their gastric motility and their dyspeptic symptoms
[29,30], it is postulated that a significant correlation can
be found between dyspeptic symptoms of FD patients
and cutaneous EGG recordings in this trial, and the
improvement in dyspeptic symptoms after the oral
administration of BST may be assessed by measuring
the changes in cutaneous EGG parameters. Correlations
in these parameters can evaluate the possibility of clini-
cal applications of cutaneous EGG in the treatment of
FD, and a detailed guide, based on biological evidences,
for treatment in FD patients.
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